tiprankstipranks
Advertisement
Advertisement

EOLS Stock Latest News

Evolus: Buy Rating Reiterated on Strong Execution, Raised Guidance and Unchanged $13 Price Target
RatingsEvolus: Buy Rating Reiterated on Strong Execution, Raised Guidance and Unchanged $13 Price Target
16d ago
EOLS
Evolus Inc. Earnings Call Signals Confident Growth
PremiumCompany Announcements
Evolus Inc. Earnings Call Signals Confident Growth
17d ago
EOLS
Evolus reports Q2 EPS (12c), consensus (4c)
PremiumThe Fly
Evolus reports Q2 EPS (12c), consensus (4c)
17d ago
EOLS
Evolus raises FY26 revenue view to $330M-$337M from $327M-$337M
PremiumThe Fly
Evolus raises FY26 revenue view to $330M-$337M from $327M-$337M
17d ago
EOLS
Evolus Expands Estyme Aesthetic Portfolio into New Markets
PremiumCompany Announcements
Evolus Expands Estyme Aesthetic Portfolio into New Markets
18d ago
8K
EOLS
Evolus expands strategic partnership with Symatese to commercialize Estyme
PremiumThe FlyEvolus expands strategic partnership with Symatese to commercialize Estyme
18d ago
EOLS
Evolus Secures U.S. Profhilo Distribution Agreement
Premium
Company Announcements
Evolus Secures U.S. Profhilo Distribution Agreement
2M ago
8K
EOLS
Evolus partners with IBSA to develop and market Profhilo in the U.S.
Premium
The Fly
Evolus partners with IBSA to develop and market Profhilo in the U.S.
2M ago
EOLS
Evolus Reaffirmed at Buy as Analyst Sees Path to Profitability and Maintains $13 Price Target
PremiumRatings
Evolus Reaffirmed at Buy as Analyst Sees Path to Profitability and Maintains $13 Price Target
2M ago
EOLS
Evolus Shareholders Elect Directors and Ratify Key Proposals
PremiumCompany Announcements
Evolus Shareholders Elect Directors and Ratify Key Proposals
2M ago
8K
EOLS
Evolus files $250M mixed securities shelf
PremiumThe Fly
Evolus files $250M mixed securities shelf
3M ago
EOLS
Evolus management to meet virtually with BTIG
PremiumThe Fly
Evolus management to meet virtually with BTIG
3M ago
EOLS
Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors
PremiumCompany AnnouncementsEvolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors
3M ago
EOLS
Evolus announces commercial launch of Estyme in Europe
Premium
The Fly
Evolus announces commercial launch of Estyme in Europe
3M ago
EOLS
Evolus Faces Heightened Operational Risk from Overseas Manufacturing and Disaster Recovery Gaps
Premium
Company Announcements
Evolus Faces Heightened Operational Risk from Overseas Manufacturing and Disaster Recovery Gaps
4M ago
EOLS
Evolus Maintains Buy Rating as Scalable Growth Story Solidifies; $13 Price Target Reaffirmed
PremiumRatings
Evolus Maintains Buy Rating as Scalable Growth Story Solidifies; $13 Price Target Reaffirmed
4M ago
EOLS
Evolus Earnings Call Highlights Profitable Growth Path
PremiumCompany Announcements
Evolus Earnings Call Highlights Profitable Growth Path
4M ago
EOLS
Evolus Ends ATM Facility After Strong Q1 Momentum
PremiumCompany Announcements
Evolus Ends ATM Facility After Strong Q1 Momentum
4M ago
8K
EOLS
Evolus reports Q1 EPS (16c), consensus (12c)
PremiumThe Fly
Evolus reports Q1 EPS (16c), consensus (12c)
4M ago
EOLS
EOLS Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsEOLS Upcoming Earnings Report: What to Expect?
4M ago
EOLS
Evolus Earnings Call Signals Growth Amid Headwinds
Premium
Company Announcements
Evolus Earnings Call Signals Growth Amid Headwinds
6M ago
EOLS
Data Privacy Compliance Risks Threaten Evolus’s Operations and Financial Health
Premium
Company Announcements
Data Privacy Compliance Risks Threaten Evolus’s Operations and Financial Health
6M ago
EOLS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >